FDA approves Revolution Medicines' Rasonque for pancreatic cancer under priority voucher program
Revolution Medicines has received FDA approval for Rasonque, a targeted pancreatic cancer therapy that was reviewed through the agency's National Priority Voucher program in a fraction of the usual time. The decision addresses a disease with a five-year survival rate of about 13 percent, one of the lowest among major cancers.
High Factuality✦ Positive
